ArticleClinical interventions in aging2026
Examining the Clinical Usefulness of Urine Methylmalonic Acid for Diagnosis of Vitamin B-12 Deficiency in Older Adults: A Pilot Study.
Article in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Vitamin B-12 deficiency is common among older adults and can lead to irreversible neurological damage and severe complications if not treated early. Despite its clinical significance, effective management remains challenging due to the absence of simple and sensitive biomarkers for early detection and for monitoring treatment response. Purpose: This pilot study evaluated the feasibility and potential of the urinary methylmalonic acid (uMMA)/creatinine ratio as a biomarker of vitamin B-12 deficiency in older adults, while exploring clinical responses following supplementation. Participants and Methods: A 3-month quasi-experimental pre-post study was conducted with 53 community-dwelling adults aged ≥70 years. Participants provided 4 monthly fasting urine samples to enable tandem mass spectrometry analysis of the uMMA/creatinine ratio before and after 1200 µg/day of peroral vitamin B-12 supplementation. Balance (Berg Balance Scale, Activities-specific Balance Confidence Scale), cognitive function (Montreal Cognitive Assessment), and neurophysiological markers (motor evoked potentials [MEP] latency) were assessed before and after supplementation. Results: All urine filter paper samples were successfully received and analyzed, with most participants (n = 45) maintaining a supplementation adherence rate of 95% or higher. Supplementation led to a statistically significant reduction in uMMA/creatinine levels, accompanied by significant improvements in both balance and cognitive performance. A significant correlation was observed between the reduction in the uMMA/creatinine ratio and cognitive improvement. No significant changes were detected in MEP latency. Conclusion: Urinary methylmalonic acid is a promising biomarker for assessing vitamin B-12 deficiency and treatment response in older adults. Larger, well-designed studies with extended supplementation periods are needed to confirm its clinical utility and better evaluate the impact of prolonged supplementation on balance, cognitive and neurophysiological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.